The early B-cell factor (EBF)-associated zinc-finger protein (EBFAZ) binds to and negatively regulates EBF, a basic helix-loop-helix transcription factor required for B-cell lineage commitment and development of the olfactory epithelium. It also binds to SMA-and MADrelated protein 1 (SMAD1) and SMAD4 in response to bone morphogenic protein 2 (BMP2) signaling. It is highly related to ecotropic viral integration site 3 (EVI3), a protein that, like EBFAZ, contains 30 Kru¨ppel-like zincfinger repeats. In previous studies, we showed that Evi3 is a frequent target of retroviral integration in AKXD27 Bcell lymphomas. Here, we show that EBFAZ is also a frequent target. Integrations at Ebfaz and Evi3 are mutually exclusive, suggesting that they function in the same tumor pathway. Lymphomas with integrations at Ebfaz or Evi3 express the pre-B-cell-specific marker immunoglobulin lambda chain 5, and contain immunoglobulin heavy-chain rearrangements, suggesting that they are blocked at an early B-cell stage. Unlike Evi3, which is expressed at low levels in normal B cells, or Ebfaz, which is not expressed in B cells, both genes are highly expressed following viral integration. Collectively, our results suggest that ectopic expression of Ebfaz can substitute for the upregulated expression of Evi3 in B-cell disease and highlight the importance of this gene family in hematopoietic cancer.
AKXD27 is one of 21 recombinant inbred strains generated from a cross of AKR/J mice, which have a high incidence of T-cell lymphoma, and the low lymphomatous strain, DBA/2J (Mucenski et al., 1986; Gilbert et al., 1993) . Like the parental AKR/J strain, AKXD27 mice develop lymphomas with a high incidence. However, unlike AKR/J mice, these lymphomas are primarily of B-cell origin (Gilbert et al., 1993) . Lymphomas in AKXD27 mice are caused by the expression of an ecotropic murine leukemia virus (MuLV), which is transmitted as an endogenous provirus in this strain. Replication-competent MuLVs induce lymphomas via insertional mutagenesis, by integrating near and deregulating the expression of proto-oncogenes, or by integrating within and inactivating the expression of tumor suppressor genes. The retroviral integrations in these tumors thus provide powerful molecular tags for cancer gene identification.
In previous studies, three of seven (43%) AKXD27 lymphomas analysed were shown to contain retroviral integrations at Evi3 (Warming et al., 2003) . All of the integrations were located upstream of the first coding exon and upregulated Evi3 expression by a promoter insertion mechanism. Evi3 encodes a novel protein with 30 Kru¨ppel-like zinc-finger repeats and is highly homologous to EBFAZ (also known as OLF1/EBFassociated zinc-finger protein, OAZ), a multifunctional signaling protein that functions in many signaling pathways via its multiple zinc-finger repeats. EBFAZ was first identified by its ability to associate with EBF (also known as olfactory 1, OLF1) in a yeast two-hybrid screen (Tsai and Reed, 1997) . EBF is required for the initiation of B-lymphopoiesis in the bone marrow (Schebesta et al., 2002) . In the absence of EBF, B-cell development is arrested at a very early stage, before D H -J H rearrangements at the Igh locus occur. Binding of EBFAZ to EBF abolishes EBF-mediated transactivation on native promoters located upstream of the olfactory marker protein and type III adenylyl cyclase genes by sequestering EBF in a heteromultimeric complex that fails to bind the EBF-binding site (Tsai and Reed, 1997) . It also binds to SMA-and MADrelated protein 1 (SMAD1) and SMAD4 in response to bone morphogenic protein 2 (BMP2) signaling (Hata et al., 2000) . The 30 EBFAZ zinc-fingers are organized into distinct clusters. The most C-terminal fingers (28-30) interact with EBF (Tsai and Reed, 1998) , whereas fingers 14-19 interact with SMAD1 and SMAD4 (Hata et al., 2000) . DNA binding is thought to occur either through fingers 2-8, together with EBF, or via fingers 9-13, in cooperation with BMP-activated SMADS (Hata et al., 2000) . Surprisingly, although EBFAZ was originally identified as an EBF-interacting protein, it is not expressed in B cells. This is in contrast to ecotropic viral integration site 3 (EVI3), which is expressed at low levels in all stages of B-cell development (Warming et al., 2003) . This suggests that EVI3 and not EBFAZ is the member of this protein family that regulates EBF signaling in B cells.
Here, we show that Ebfaz is also a frequent target of retroviral integration in AKXD27 lymphomas. Among nine AKXD27 lymphomas analysed, three had retroviral integrations at Ebfaz (Figure 1 ). These integrations were initially located B100 kb upstream of Ebfaz. However, by examining the public expressed sequence tag (EST) database, we were able to identify two additional upstream Ebfaz coding exons (exons 1 and 2, Figure 1a ) that were later confirmed by polymerase chain reaction (PCR) amplification and DNA sequencing of reverse transcribed (RT) Ebfaz mRNA to be authentic Ebfaz coding exons. The addition of these two coding exons places the three Ebfaz integrations between 450 and 650 bp upstream of Ebfaz exon 1 (Figure 1a) . The discovery of two additional Ebfaz coding exons extends the EBFAZ N-terminus by 21 amino acids, but the overall structure of the protein, including the 30 Kru¨ppel-like zinc-fingers, (Figure 2 ) remains unchanged. With the addition of these two coding exons, the 11 most N-terminal amino acids of EBFAZ and EVI3 are now identical.
The Ebfaz integrations were identified by inverse PCR as described by Li et al. (1999) . It is therefore possible that these integrations are present in only a subpopulation of the tumor cells. This could occur if for instance these integrations were important for the progression rather than the initiation of tumor development. To determine if this is the case, the three lymphomas with Ebfaz integrations were analysed by Southern analysis using an Ebfaz-specific probe. As shown in Figure 1b , all three lymphomas with retroviral integrations at Ebfaz carried clonal integrations at Ebfaz (i.e., the integrations are present in most if not all tumor cells), suggesting that these integrations occurred early in tumor development and may therefore be involved in tumor initiation.
Ecotropic and mink cell focus forming (MCF) class II MuLVs contain single asymmetrically located SacI restriction enzyme cleavage sites ( Figure 1c ). Based upon the size of the rearranged SacI fragments detected on Southern blots ( Figure 1b ) and the orientation of the proviral integration sites determined by genomic sequencing, we infer that the integrations in tumors 6895 and 7403 are ecotropic proviruses, while the integration in tumor 26 is an MCF class II provirus ( Figure 1c ). Real-time RT-PCR expression analysis of the nine lymphomas analysed for Ebfaz integrations showed that the three lymphomas with Ebfaz integrations expressed higher levels of Ebfaz than the lymphomas without Ebfaz integrations (Figure 3a) .
Southern analysis of immunoglobulin and T-cell receptor gene rearrangements in AKXD27 lymphomas with Evi3 integrations indicated that these lymphomas were B cell in origin (Justice et al., 1994; Warming et al., 2003) . The same appears to be true for lymphomas with Ebfaz integrations. All lymphomas with Ebfaz integrations (tumors 26, 6895, 7403) carry immunoglobulin heavy-chain gene rearrangements and lack T-cell receptor gene rearrangements (data not shown). They also express the pre-B-cell-specific marker immunoglobulin lambda chain 5 (Igl5) (Sakaguchi and Melchers, 1986; Kudo and Melchers, 1987) (Figure 3b ). The expression of Igl5 suggests that these lymphomas are blocked at an early B-cell stage. Surprisingly, none of the lymphomas with retroviral integrations at Ebfaz stained positive for the B-cell marker B220 (Coffman and Weissman, 1981) (data not shown). The reason for this remains unclear. Lymphomas with retroviral integrations at Evi3 (tumors 22, 27, 29) also express Igl5, indicating that they are also blocked at an early B-cell stage (Figure 3b ). Southern blot analysis of SacI-digested DNA from nine AKXD27 lymphomas. The blots were hybridized according to standard procedures with an Ebfaz-specific genomic probe generated by PCR amplification using the following primers: 5 0 -AG-CAGGGGTGAAGACAGTTA-3 0 and 5 0 -GTCGGAGGTGGCA-GAAACA-3 0 and BAC DNA as template. Primers were purchased from Integrated DNA Technologies, Inc. (Coralville, IA, USA) and PCR was carried out using the Expand High Fidelity PCR kit (Roche Applied Science, Indianapolis, IN, USA). (c) A model to explain the band sizes observed in (b). The exact integration site and orientation relative to Ebfaz was determined using inverse PCR followed by cloning, essentially as described (Suzuki et al., 2002) . The figure explains how the unique SacI site asymmetry can be used to distinguish ecotropic proviral integrations from MCF class II proviral integrations Ebfaz activation in murine lymphoma S Warming et al tumors with integrations at Evi3 or Ebfaz could therefore be an indirect result of Evi3/Ebfaz overexpression through inhibition of EBF. Alternatively, the tumorinitiating cell could already have been arrested at the pre-B stage due to another genetic event prior to retroviral integration into Ebfaz or Evi3.
Real-time RT-PCR analysis of Ebfaz expression in adult mouse tissues showed that Ebfaz expression is highest in smooth muscle, brain, lung and heart (Figure 4a ). Ebfaz expression was not detectable in hematopoietic tissues such as the bone marrow, spleen, thymus and lymph node. Whole-mount in situ hybridization showed that Ebfaz is also expressed in the embryo at all developmental stages analysed (E6.5-E10.5, E12.5) (Figure 4b -f and data not shown). Ebfaz expression was detected throughout the embryonic ectoderm (epiblast) at pregastrulation stages (E6.5, not shown) and was not detected in extraembryonic tissues until E7.5, where it was expressed in the extraembryonic mesoderm of the developing alantois. At E7.5, Ebfaz was expressed in posterior embryonic ectoderm, the anterior and lateral boundaries of the future neural plate and in the posterior embryonic mesoderm as it exited the primitive streak, (Figure 4b ). Ebfaz continued to be expressed strongly throughout the neural plate and tube at E8-8.5, including the forebrain, midbrain, hindbrain, spinal cord and in the posterior streak ectoderm (Figure 4c ). Transcripts were found in the presomitic mesoderm, somites and alantois, but were undetectable in the heart, yolksac and axial mesendoderm derivatives. At E9.5, Ebfaz was broadly expressed throughout the brain and spinal cord, somites, tailbud and craniofacial primordia (data not shown). The pattern of Ebfaz expression in these tissues was similar between E9.5-E12.5 with additional sites of expression in the developing limbs (Figure 4d and e) , whisker barrels and olfactory bulb progenitors (Figure 4f and data not shown). These results are consistent with the notion that EBFAZ is a multifunctional signaling protein that operates in many signaling pathways and 0 SalI site (5 0 -AAATAAGTCGACTGCCGCATTGCAACAGGCA-3 0 , the SalI site is underlined). Primers were purchased from Integrated DNA Technologies, Inc. The PCR was performed using the Expand High Fidelity PCR kit in the presence of 5% formamide and 5% dimethylsulfoxide (DMSO), both from Sigma-Aldrich (Milwaukee, WI, USA) under the following conditions: 941C for 15 s, 601C for 1 min, 721C for 1 min 30 s for 35 cycles. The PCR product was double digested with SalI and ApaLI and substituted for the 5 0 end of the Ebfaz cDNA previously cloned form our laboratory (GenBank Accession No. AY147407). The predicted translation start site (ATG) is underlined and all 30 Kru¨ppel-like zinc-fingers are highlighted. The cDNA sequence has been deposited in GenBank under Accession No. AY256893
Ebfaz activation in murine lymphoma S Warming et al diverse tissues, including the olfactory epithelium. They are also consistent with previous studies suggesting EVI3 and not EBFAZ is the family member that is important in hematopoiesis. For comparison, in Xenopus, at the tadpole stage, Ebfaz (Xoaz) expression is not expressed in the spinal cord but restricted to and highly expressed in the forebrain, midbrain and hindbrain (Hata et al., 2000) .
Integrations at Ebfaz and Evi3 are likely to be mutually exclusive since in no case did we identify a lymphoma that had integrations at both Ebfaz and Evi3. These results suggest that EBFAZ and EVI3 function in the same tumor pathway. EVI3 is expressed at low levels throughout B-cell development, but at much higher levels following retroviral integration at Evi3 (Justice et al., 1994; Warming et al., 2003) . It has been hypothesized that retroviral-induced upregulation of EVI3 induces B-cell lymphoma by binding to and inhibiting EBF activity in B cells in a manner analogous to what has been described for EBFAZ (Tsai and Reed, 1997) , resulting in a block in B-cell differentiation (Warming et al., 2003) . These results are consistent with the results reported here, suggesting that B-cell lymphomas with retroviral integrations at Evi3 are blocked at an early B-cell stage. EBFAZ is not normally expressed in B cells. It is, however, ectopically expressed at high levels following retroviral integration. Given the high degree of sequence similarity between EBFAZ and EVI3 and the similar B-cell differentiation block observed in lymphomas with integrations at Ebfaz, it appears likely that ectopic expression of EBFAZ can function in an Figure 4 Ebfaz expression in adult and embryonic mouse tissues. (a) Ebfaz expression in 12 adult mouse tissues (multiple tissue cDNA panels I þ II, Clontech, BD Biosciences) determined by realtime PCR. H, heart; Lu, lung; Li, liver; Ki, kidney; Sk, skeletal muscle; Sm, smooth muscle (small intestine); Br, brain; E, eye; Bm, bone marrow; Sp, spleen; Th, thymus; and Ln, lymph node. Primers were the same as described in Figure 3a. (b-f) Ebfaz expression during embryonic development determined by wholemount in situ hybridization. A 1.4 kb fragment corresponding to the 5 0 end of the Ebfaz open reading frame was used to generate an antisense Ebfaz probe. In situ hybridization was performed according to standard procedures. (f) Close-up of the facial region of an E12.5 embryo to show Ebfaz expression in the whisker barrels and olfactory bulb progenitors. (g) The same 1.4 kb fragment described in (b) was used to generate a sense Ebfaz probe in order to control for the specificity of hybridization. Embryonic stages are indicated in the upper left corners Ebfaz activation in murine lymphoma S Warming et al analogous manner to the deregulated expression of EVI3 in B-cell lymphomagenesis. Retroviral integrations at Evi3 have been found in Bcell lymphomas from several different AKXD strains (AKXD2, AKXD9, AKXD14 and AKXD27) (Justice et al., 1994) . However, Evi3 integrations are most frequently found in AKXD27 lymphomas. So far, retroviral integrations at Ebfaz have only been identified in AKXD27 lymphomas, although, to date, this is the only AKXD strain examined for Ebfaz integrations so it remains possible that Ebfaz integrations will be found in other AKXD strain tumors as well. Interestingly, in the SL/Kh mouse model for pre-B lymphomas, Evi3 is the most frequent site of retroviral integration (75% of tumors) (Hiai et al., 2003) . It will be interesting to determine whether SL/Kh lymphomas also contain retroviral integrations at Ebfaz.
The human orthologs of Ebfaz (OAZ) and Evi3 (early hematopoietic zinc-finger gene, EHZF) map to 16q12 and 18q11.2, respectively. Duplications and deletions of 16q12 have been identified in multiple myeloma (Seong et al., 1998; Smadja et al., 2001 ) and acute lymphoblastic leukemia (Heerema et al., 1999) , while translocations involving 18q11 have been seen in acute lymphoblastic leukemia (Hilden et al., 1995; Heerema et al., 1999) . Given the results reported here, it would not be surprising to find that OAZ and EHZF are also human leukemia disease genes.
